Основная статистика
| CIK | 1674365 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aptinyx Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 9, 2024 |
APTX / Aptinyx Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) APTINYX INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of Incorporation) (Commission File Num |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of Incorporation) (Commission File Num |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of Incorporation) (Commission File Number) |
|
| June 27, 2023 |
APTX / Aptinyx Inc / ADAMS STREET PARTNERS LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N103 (Cusip Number) Elisha (“Terry”) P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (312) 553-7890 (Name, Address and Telephone Number of Person Auth |
|
| June 2, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 24, 2023 |
As filed with the Securities and Exchange Commission on May 24, 2023 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. |
|
| May 24, 2023 |
As filed with the Securities and Exchange Commission on May 24, 2023 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. |
|
| May 24, 2023 |
APTINYX INC. c/o Verdolino & Lowey, P.C. 124 Washington Street, Suite 101 Foxborough, MA (508) 543-1270 May 24, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: Aptinyx Inc. – Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-263808) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under t |
|
| May 24, 2023 |
As filed with the Securities and Exchange Commission on May 24, 2023 S-8 POS 1 tm2316622d1s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. 333-263788 Registration No. 333-254665 Registration No. 333-237508 Registration No. 333-225801 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263788 POST-EFFECTIVE AMENDMENT NO. |
|
| May 24, 2023 |
As filed with the Securities and Exchange Commission on May 24, 2023 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. |
|
| May 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Perio |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 5, 2023 |
Plan of Dissolution of Aptinyx Inc. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF APTINYX INC. This Plan of Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of APTINYX INC., a Delaware corporation (such corporation or a successor entity, the “Company”), in accordance with Section 281(b) of the General Corporation Law of the State of Delaware (the “DGCL”). 1. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-3853 |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2023 |
Description of Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its e |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38535 |
|
| March 30, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Aptinyx Inc. None |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2023 |
Exhibit 99.1 Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives EVANSTON, Ill., March 30, 2023 - Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates · In March, Aptinyx completed an analysis of the data from the first 100 patients enr |
|
| March 16, 2023 |
EX-99.6 Exhibit 99.6 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Cristiana Blauth Oliveira as the undersigned’s true and lawful attorney-in-fact (the “Attorney-in-Fact”) to: 1. execute for and on behalf of the undersigned (the “Reporting Person”) a Form ID Application and/or “Update Passphrase Confirmation,” if required, and submit the same to |
|
| March 16, 2023 |
EX-99.7 Exhibit 99.7 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Cristiana Blauth Oliveira as the undersigned’s true and lawful attorney-in-fact (the “Attorney-in-Fact”) to: 1. execute for and on behalf of the undersigned (the “Reporting Person”) a Form ID Application and/or “Update Passphrase Confirmation,” if required, and submit the same to |
|
| March 16, 2023 |
APTX / Aptinyx Inc / Longitude Capital Partners II, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03836N103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-57 |
|
| March 1, 2023 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 27, 2023 |
Exhibit 99.1 Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The c |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 14, 2023 |
APTX / Aptinyx Inc / Longitude Capital Partners II, LLC - SC 13D/A Activist Investment SC 13D/A 1 d461612dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03836N103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Men |
|
| February 13, 2023 |
APTX / Aptinyx Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) APTINYX INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 20, 2023 |
APTX / Aptinyx Inc / Kryzanowski John A Passive Investment SC 13G/A 1 aptinyx13gamd4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Aptinyx Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| December 8, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 7, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 8, 2022 |
Exhibit 99.1 Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Man |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2022 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No. |
|
| August 25, 2022 |
Exhibit 99.1 Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson?s Disease and Dementia with Lewy Bodies Results from the Phase 2 study are expected in 1Q 2023 EVANSTON, Ill., August 25, 2022 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous syst |
|
| August 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 25, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2022 |
Exhibit 99.1 Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia NYX-2925 did not achieve the primary endpoint of the study EVANSTON, Ill., August 12, 2022 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study ev |
|
| August 4, 2022 |
Exhibit 99.1 Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No. |
|
| June 24, 2022 |
APTX / Aptinyx Inc / Kryzanowski John A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Aptinyx Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 24, 2022 |
APTX / Aptinyx Inc / Kryzanowski John A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Aptinyx Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 24, 2022 |
APTX / Aptinyx Inc / Kryzanowski John A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Aptinyx Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 24, 2022 |
APTX / Aptinyx Inc / Kryzanowski John A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Aptinyx Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 03836N103 (CUSIP Number) November 5, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| June 10, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 31, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2022 |
Exhibit 99.1 Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout from exploratory Phase 2 study of NYX-458 in cogni |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 14, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 7, 2022 |
Exhibit 99.1 Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy NYX-2925 did not achieve the primary endpoint of the study EVANSTON, Ill., April 7, 2022 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Ph |
|
| March 31, 2022 |
Up to $75,000,000 Common Stock TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5)? ?Registration No.: 333-263808? PROSPECTUS Up to $75,000,000 Common Stock We have entered into a sales agreement, or the Original Sales Agreement, as amended by Amendment No. 1 to Sales Agreement dated March 24, 2022, or the Amendment and together with the Original Sales Agreement, the Sales Agreement, with Cowen and Company, LLC, or Cowen, relat |
|
| March 29, 2022 |
Aptinyx Inc. 909 Davis Street, Suite 600 Evanston, Illinois 60201 Aptinyx Inc. 909 Davis Street, Suite 600 Evanston, Illinois 60201 March 29, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aptinyx Inc.: Registration Statement on Form S-3 filed March 24, 2022 (File No. 333-263808) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, |
|
| March 24, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-3 (Form Type) Aptinyx Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forw |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 24, 2022. |
|
| March 24, 2022 |
Form of Subordinated Indenture (including Form of Subordinated Note) Exhibit 4.4 APTINYX INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS(1) ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section |
|
| March 24, 2022 |
Form of Senior Indenture (including Form of Senior Note) Exhibit 4.3 APTINYX INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS(1) ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03 |
|
| March 24, 2022 |
Exhibit 1.3 AMENDMENT NO. 1 TO SALES AGREEMENT March 24, 2022 Aptinyx Inc. 909 Davis Street, Suite 600 Evanston, IL 60201 Ladies and Gentlemen: Aptinyx Inc., a Delaware corporation (the ?Company?), together with Cowen and Company, LLC (the ?Agent?), are parties to that certain Sales Agreement dated September 16, 2021 (the ?Original Agreement?). All capitalized terms not defined herein shall have t |
|
| March 23, 2022 |
Subsidiaries of the Registrant ? Exhibit 21.1 Subsidiaries of Aptinyx Inc. None ? |
|
| March 23, 2022 |
Description of Registrant’s Securities ? Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in i |
|
| March 23, 2022 |
As filed with the Securities and Exchange Commission on March 23, 2022 As filed with the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Aptinyx Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Rate Fee Amount of Registration Fee Equity Com |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2022 |
Non-Employee Director Compensation Policy. ? Exhibit 10.5 APTINYX INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this NON-EMPLOYEE DIRECTOR COMPENSATION POLICY of Aptinyx Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| March 23, 2022 |
Exhibit 99.1 Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights Data readouts from Phase 2b studies of NYX-2925 in painful DPN and fibromyalgia expected in April 2022 and early to mid 3Q 2022, respectively Ongoing Phase 2 study in cognitive impairment expected to read out in late 2022 or 1Q 2023 Initiated Phase 2b study of NYX-783 50 mg in PTSD in 4Q 2021; Phase 2b study of N |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 28, 2022 |
Exhibit 99.1 Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia Results from the Phase 2b study are expected in early to mid 3Q 2022 EVANSTON, Ill., February 28, 2022 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollme |
|
| February 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 11, 2022 |
APTX / Aptinyx Inc / New Leaf Ventures III, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 03836N103 (CUSIP Number) New Leaf Ventures 420 Lexington Avenue, Suite 408 New York, NY 10170 Attn: Craig Slutzkin (646) 871-6400 Gunderson Dettmer Stough Villeneu |
|
| February 9, 2022 |
R&D and Portfolio Review February 9, 2022 Exhibit 99.1 R&D and Portfolio Review February 9, 2022 2 February 2022 Forward - looking statements This presentation contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 19 95 relating to business, operations, and financial conditions of Aptinyx, including, but not limited to, Aptinyx?s belief in the po tential benefit and profile of its prod |
|
| February 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 3, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this ?Amendment?) is made effective as of January 1, 2022 (the ?Amendment Effective Date?), by and between Aptinyx, Inc. (the ?Company?), and Andrew D. Kidd (the ?Executive?). WITNESSETH WHEREAS, the Company and the Executive are parties to an Amended and Res |
|
| January 3, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this ?Amendment?) is made effective as of January 1, 2022 (the ?Amendment Effective Date?), by and between Aptinyx, Inc. (the ?Company?), and Norbert G. Riedel, PhD (the ?Executive?). WITNESSETH WHEREAS, the Company and the Executive are parties to an Amended |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 9, 2021 |
Exhibit 99.1 Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022 PTSD Phase 2b program is set to initiate in 4Q |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No. |
|
| October 27, 2021 |
Exhibit 99.1 Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Results from the Phase 2b study are expected in early to mid 2Q 2022 EVANSTON, Ill., October 27, 2021 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced t |
|
| October 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 20, 2021 |
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors Exhibit 99.1 Aptinyx Appoints Gilmore O?Neill, M.B., M.M.Sc., to Board of Directors EVANSTON, Ill., October 20, 2021 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O?Neill, M.B., M.M.Sc., to the company?s board of directors. Dr. O?Neill currently |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 19, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 16, 2021 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| September 16, 2021 |
Exhibit 1.2 APTINYX Inc. $50,000,000 Common stock SALES AGREEMENT September 16, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Aptinyx Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreemen |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 16, 2021 |
Exhibit 1.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of September 15, 2021 (the ?Closing Date?) is entered into among APTINYX INC., a Delaware corporation (?Borrower Representative?), and each other Person party hereto as a borrower from time to time (collectively, ?Borrowers |
|
| September 16, 2021 |
Up to $50,000,000 Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-232488? PROSPECTUS SUPPLEMENT (To Prospectus dated July 8, 2019) Up to $50,000,000 Common Stock We have entered into a sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.01 per share, offered by this prospectus supplement. In accordance with the t |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2021 |
Exhibit 99.1 Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights Enrollment on track in both Phase 2b chronic pain studies with NYX-2925?data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458?data readout expected 2H 2022 Completed FDA meeting on NYX-783 development?expect to initiate Phase 2b studies in PTSD in 4Q 2021 and 1 |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No. |
|
| June 15, 2021 |
Exhibit 99.3 Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation June 2021 Nasdaq: APTX This presentation has been prepared by Aptinyx Inc. (?we,? ?us,? ?our,? ?Aptinyx,? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any secu |
|
| June 15, 2021 |
Exhibit 99.1 Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021 Corrects statistical analysis from previous exploratory Phase 2 study?no impact on study conclusions or future clinical development plans EVANSTON, Ill. - (June 15, 2021) - Aptinyx Inc. (Nasdaq: |
|
| June 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| June 15, 2021 |
Exhibit 99.2 Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation June 2021 Nasdaq: APTX This presentation has been prepared by Aptinyx Inc. (?we,? ?us,? ?our,? ?Aptinyx,? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any secu |
|
| June 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 27, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. E |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2021 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No. |
|
| May 13, 2021 |
EX-99.1 2 tm2116239d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aptinyx Reports First Quarter 2021 Financial Results and Highlights Enrollment on track in both Phase 2b studies of NYX-2925 in chronic pain—data readouts expected 1H 2022 Preparing for NYX-783 Phase 2b PTSD study following recent FDA meeting — study initiation expected in 2H 2021 Recommenced Phase 2 study of NYX-458 in patients with cognit |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2021 |
Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors Exhibit 99.1 Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors EVANSTON, Ill., May 10, 2021 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company?s Board of Directors. Dr. Miller currently serves as the David |
|
| May 4, 2021 |
SC 13D/A 1 d114529dsc13da.htm AMENDMENT NO. 3 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N 103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 T |
|
| April 13, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 26, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| March 24, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| March 24, 2021 |
EX-99.1 2 tm2110648d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Phase 2 studies in fibromyalgia and painful DPN enrolling as planned – data readouts expected in 1H 2022 Phase 2 study in cognitive impairment expected to recommence imminently – data readout expected in 2H 2022 Reported data from Phase 2 explo |
|
| March 24, 2021 |
Non-Employee Director Compensation Policy. ? Exhibit 10.5 APTINYX INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this NON-EMPLOYEE DIRECTOR COMPENSATION POLICY of Aptinyx Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| March 24, 2021 |
Description of Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its |
|
| March 24, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Aptinyx Inc. None |
|
| March 24, 2021 |
Form S-8 (File No. 333-254665) filed on March 24, 2021 As filed with the Securities and Exchange Commission on March 24, 2021 Registration No. |
|
| February 4, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N 103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone |
|
| January 29, 2021 |
Exhibit 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, par value $0. |
|
| January 29, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) APTINYX INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) January 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| December 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 16, 2020 |
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer Exhibit 99.1 Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer EVANSTON, Ill., December 16, 2020 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company’s current chief operating officer, to the role of presid |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| November 12, 2020 |
Exhibit 99.1 Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights Significant development progress across clinical-stage pipeline programs, with multiple clinical and regulatory milestones expected over the next 18 months Recommenced patient recruitment in Phase 2b clinical study of NYX-2925 in patients with fibromyalgia Near-term recommencements planned for Phase 2b clinical |
|
| October 27, 2020 |
APTX / Aptinyx Inc. / Bain Capital Life Sciences Fund, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d41580dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) Aptinyx Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Tit |
|
| October 22, 2020 |
Aptinyx Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., – October 21, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3 |
|
| October 22, 2020 |
Aptinyx Announces Proposed Public Offering of Common Stock Exhibit 99.1 Aptinyx Announces Proposed Public Offering of Common Stock EVANSTON, Ill., October 20, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All |
|
| October 22, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 22, 2020 |
Exhibit 1.1 UNDERWRITING AGREEMENT APTINYX INC. 14,000,000 Shares of Common Stock, par value $0.01 per share October 21, 2020 SVB Leerink LLC Piper Sandler & Co. Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 c/o Piper Sandler & Co. 345 Park Avenue, Suite 1200 Ne |
|
| October 22, 2020 |
14,000,000 Shares Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 20, 2020 |
Phase 2 PTSD Study Top - Line Results October 20, 2020 Exhibit 99.1 Phase 2 PTSD Study Top - Line Results October 20, 2020 This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informat ion al purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securitie s i n any state or jurisdiction in which such offe |
|
| October 20, 2020 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 20, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 20, 2020 |
SUBJECT TO COMPLETION, DATED OCTOBER 20, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 19, 2020 |
Exhibit 99.1 Aptinyx Reports Positive, Statistically Significant, Top-line Data from Phase 2 Study of NYX-783 in Patients with Post-Traumatic Stress Disorder Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783 Clinically meaningful improvement from baseline on CAPS-5 Total Score observed in 50 mg dose arm Statistically signif |
|
| October 19, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 19, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 28, 2020 |
Exhibit 99.1 Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia Resuming study following suspension of enrollment due to escalation of COVID-19 pandemic Data readout expected in 1H 2022 Also on track to recommence separate Phase 2 study of NYX-2925 in painful DPN in 4Q 2020 EVANSTON, Ill., September 28, 2020 - Aptinyx Inc. (Nasdaq: APTX), a clinical- |
|
| September 28, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S |
|
| August 13, 2020 |
Exhibit 99.1 Aptinyx Reports Second Quarter 2020 Financial Results and Highlights Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020 Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon Conference call today at 5:00 p.m. ET EVANSTON, Ill., August 13, 2020 - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical com |
|
| August 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| August 5, 2020 |
Exhibit 99.1 Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation August 2020 Nasdaq: APTX Forward-looking statements This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall |
|
| August 5, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 22, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. E |
|
| May 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 14, 2020 |
Exhibit 99.1 Aptinyx Reports First Quarter 2020 Financial Results and Highlights Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., May 14, 2020 - Aptinyx Inc. (Nasdaq: APTX), a clinical- |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 6, 2020 |
APTX / Aptinyx Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 6, 2020 |
Use these links to rapidly review the document Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2020 |
Form S-8 (File No. 333-237508) filed on March 31, 2020 As filed with the Securities and Exchange Commission on March 31, 2020 Registration No. |
|
| March 30, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Aptinyx Inc. None |
|
| March 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| March 30, 2020 |
APTX / Aptinyx Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑38535 AP |
|
| March 30, 2020 |
Exhibit 99.1 Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common stock offering provides runway into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill. |
|
| March 30, 2020 |
APTINYX INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.5 APTINYX INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this NON-EMPLOYEE DIRECTOR COMPENSATION POLICY of Aptinyx Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose |
|
| March 30, 2020 |
Description of Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its e |
|
| February 14, 2020 |
APTX / Aptinyx Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Aptinyx Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2019 Date of Event Which Requires Filing of |
|
| February 13, 2020 |
APTX / Aptinyx Inc. / New Leaf Ventures III, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 03836N103 (CUSIP Number) New Leaf Ventures 420 Lexington Avenue, Suite 408 New York, NY 10170 Attn: Craig Slutzkin (646) 871-6400 Gunderson Dettmer Stough |
|
| February 13, 2020 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.E Exhibit E AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Date: Febr |
|
| February 12, 2020 |
APTX / Aptinyx Inc. / Longitude Capital Partners II, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03836N103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-57 |
|
| January 17, 2020 |
APTX / Aptinyx Inc. / ADAMS STREET PARTNERS LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N103 (Cusip Number) Elijah (“Terry”) P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (Name, Address and Telephone Number of Person Authorized to Receiv |
|
| January 16, 2020 |
APTX / Aptinyx Inc. / Bain Capital Life Sciences Fund, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 16, 2020 |
APTX / Aptinyx Inc. / Frazier Life Sciences Viii, L.p. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N 103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone |
|
| January 13, 2020 |
Exhibit 1.1 UNDERWRITING AGREEMENT APTINYX INC. 10,166,666 Shares of Common Stock, par value $0.01 per share January 10, 2020 Cowen and Company, LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Aptinyx Inc., a Delaware corporation (the “Company”), proposes to issue and sell t |
|
| January 13, 2020 |
Prospectus Supplement (to Prospectus dated July 8, 2019) Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424b(5) Registration No. |
|
| January 13, 2020 |
Aptinyx Announces Proposed Public Offering of Common Stock Exhibit 99.1 Aptinyx Announces Proposed Public Offering of Common Stock Evanston, Ill., January 09, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shar |
|
| January 13, 2020 |
Aptinyx Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., – January 10, 2020 – Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering price of $3. |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S |
|
| January 9, 2020 |
SUBJECT TO COMPLETION, DATED JANUARY 9, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424b(5) Registration No. |
|
| December 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (C |
|
| November 12, 2019 |
APTX / Aptinyx Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| November 12, 2019 |
Exhibit 99.1 Aptinyx Reports Third Quarter 2019 Financial Results and Highlights Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00 p.m. EST EVANSTON, Ill., November 12, 2019 — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company dev |
|
| September 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): August 28, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S |
|
| September 4, 2019 |
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors Exhibit 99.1 Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors EVANSTON, Ill., September 4, 2019 — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Rachel Sherman, M.D., M.P.H., former principal deputy |
|
| August 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 12, 2019 |
Exhibit 99.1 Aptinyx Reports Second Quarter 2019 Financial Results and Highlights Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates Conference call today at 8:00 a.m. ET EVANSTON, Ill., August 12, 2019 — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biop |
|
| August 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2019 |
APTX / Aptinyx Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| July 9, 2019 |
Up to $24,000,000 Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424b(5) Registration No. |
|
| July 3, 2019 |
APTX / Aptinyx Inc. CORRESP - - Aptinyx Inc. 909 Davis Street, Suite 600 Evanston, IL 60201 July 3, 2019 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aptinyx Inc. Registration Statement on Form S-3 filed July 1, 2019 (File No. 333-232488) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| July 1, 2019 |
Sales Agreement dated July 1, 2019 by and among the Registrant and Cowen and Company, LLC Exhibit 1.2 APTINYX INC. $50,000,000 COMMON STOCK SALES AGREEMENT July 1, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Aptinyx Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on |
|
| July 1, 2019 |
APTX / Aptinyx Inc. S-3 - - S-3 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on July 1, 2019. |
|
| July 1, 2019 |
Form of Senior Indenture (including Form of Senior Note) Exhibit 4.3 APTINYX INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·] Senior Debt Securities TABLE OF CONTENTS(1) ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 |
|
| July 1, 2019 |
Form of Subordinated Indenture (including Form of Subordinated Note) Exhibit 4.4 APTINYX INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·] Subordinated Debt Securities TABLE OF CONTENTS(1) ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section |
|
| June 10, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 10, 2019 |
Exhibit 99.1 Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with patient-reported pai |
|
| May 17, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 47-4626057 (State or other jurisdiction (Commission (I.R.S. Employer of incorporati |
|
| May 14, 2019 |
Exhibit 99.1 Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill., May 14, 2019 — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapie |
|
| May 14, 2019 |
APTX / Aptinyx Inc. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation or organization) (Commission File Nu |
|
| May 1, 2019 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 1, 2019 |
Use these links to rapidly review the document Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 21, 2019 |
Exhibit 99.1 Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress Completed Phase 2 study of NYX-2925 in painful DPN — did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant patient sub-group Reported positive data from interim analysis of Phase 2 exploratory neuroimagin |
|
| March 21, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 21, 2019 |
APTX / Aptinyx Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑38359 AP |
|
| March 21, 2019 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Aptinyx Inc. None |
|
| March 13, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora |
|
| March 13, 2019 |
Exhibit 99.1 Innovative Therapies for Disorders of the Brain and Nervous System Discovering and Developing Novel Small-Molecule NMDAr Modulators Cowen and Company 39th Annual Health Care Conference Forward-looking statements This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an off |
|
| March 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 14, 2019 |
APTX / Aptinyx Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aptinyx Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) December 31, 2018 Date of Event Which Requires Filing of |
|
| February 13, 2019 |
APTX / Aptinyx Inc. / ADAMS STREET PARTNERS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 0386N103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 13, 2019 |
AGREEMENT TO MAKE A JOINT FILING EXHIBIT 1 AGREEMENT TO MAKE A JOINT FILING The undersigned hereby agree that this Schedule 13G is filed by and on behalf of each of them. |
|
| January 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 16, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2019 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 16, 2019 |
Exhibit 99.1 Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in subjects not taking a concomitant analgesic medication NYX-2925 was well-tol |
|
| November 13, 2018 |
Exhibit 99.1 Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to announce data from interim analysis of exploratory fibromyalgia study in December 2018 EVANSTON, Ill., Nov. 13, 2018 — Aptinyx |
|
| November 13, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2018 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 13, 2018 |
APTX / Aptinyx Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| August 14, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2018 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 14, 2018 |
Exhibit 99.1 Aptinyx Reports Second Quarter 2018 Financial and Business Results Completed upsized initial public offering that raised $117.8 million in gross proceeds EVANSTON, IL – Aug 14, 2018 – Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and bu |
|
| August 14, 2018 |
APTX / Aptinyx Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| August 6, 2018 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Aptinyx Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. |
|
| August 6, 2018 |
APTX / Aptinyx Inc. / Partner Fund Management, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Aptinyx Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 03836N103 (CUSIP Number) July 26, 2018 Date of Event Which Requires Filing of the S |
|
| July 5, 2018 |
EX-99.A Exhibit A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need to be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Aptinyx Inc. Date: July 3, 2018 FRAZIER LIFE SCIENCES VIII, L.P. By FHM Life Sciences VIII, |
|
| July 5, 2018 |
APTX / Aptinyx Inc. / Frazier Life Sciences Viii, L.p. - SC 13D Activist Investment SC 13D 1 d649710dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Aptinyx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03836N 103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Nam |
|
| July 5, 2018 |
FORM OF LOCK-UP AGREEMENT FORM OF LOCK-UP AGREEMENT EX-99.B Exhibit B FORM OF LOCK-UP AGREEMENT FORM OF LOCK-UP AGREEMENT March 15, 2018 J. P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC LEERINK PARTNERS LLC BMO CAPITAL MARKETS CORP. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LL |
|
| July 3, 2018 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Date: July |
|
| July 3, 2018 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.A EXHIBIT A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule (including amendments thereto) jointl |
|
| July 3, 2018 |
APTX / Aptinyx Inc. / New Leaf Ventures III, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 03836N103 (CUSIP Number) New Leaf Ventures 7 Times Square, Suite 3502 New York, NY 10036 Attn: Craig Slutzkin (646) 871-6400 Gunderson Dettmer Stough Villene |
|
| July 3, 2018 |
EX-99.C EXHIBIT C FORM OF LOCK-UP AGREEMENT [ ], 2018 J. P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC LEERINK PARTNERS LLC BMO CAPITAL MARKETS CORP. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York |
|
| July 3, 2018 |
APTX / Aptinyx Inc. / Bain Capital Life Sciences Fund, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| July 3, 2018 |
FORM OF LOCK-UP AGREEMENT FORM OF LOCK-UP AGREEMENT EX-99.B Exhibit B FORM OF LOCK-UP AGREEMENT FORM OF LOCK-UP AGREEMENT March 15, 2018 J. P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC LEERINK PARTNERS LLC BMO CAPITAL MARKETS CORP. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LL |
|
| July 2, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time |
|
| July 2, 2018 |
Exhibit 99.2 FORM OF LOCK-UP AGREEMENT March 19, 2018 J. P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC LEERINK PARTNERS LLC BMO CAPITAL MARKETS CORP. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York |
|
| July 2, 2018 |
APTX / Aptinyx Inc. / Longitude Capital Partners II, LLC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) APTINYX INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03836N103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-5700 (Name, |
|
| June 25, 2018 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APTINYX INC. Aptinyx Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Aptinyx Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was June 24, |
|
| June 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2018 APTINYX INC. (Exact name of registrant as specified in its charter) Delaware 001-38535 45-4626057 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2018 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF APTINYX INC. (the “Corporation”) ARTICLE 1 STOCKHOLDERS Section 1.1 Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subsequen |
|
| June 21, 2018 |
Form S-8 (File No. 333-225801) filed on June 21, 2018 As filed with the Securities and Exchange Commission on June 21, 2018 Registration No. |
|
| June 21, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| June 21, 2018 |
As filed with the Securities and Exchange Commission on June 20, 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Aptinyx Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-4626057 (State or other jurisdiction of incorporation or organization) (Primary Stand |
|
| June 18, 2018 |
VIA EDGAR June 18, 2018 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| June 18, 2018 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Leerink Partners LLC 299 Park Avenue, 21st Floor New York, New York 10171 BMO Capital Markers Corp. 3 Times Square New York, New York 10036 June 18, 2018 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 205 |
|
| June 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Aptinyx Inc. (Exact name of registrant as specified in its charter) Delaware 45-4626057 (State of incorporation or organization) (I.R.S. Employer Identification No.) 909 Davis Street, Suite 600 Eva |
|
| June 11, 2018 |
Exhibit 10.2 APTINYX INC. 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Aptinyx Inc. 2018 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Aptinyx Inc. (the ?Company?) and its Subsidiaries upon whose judgment, init |
|
| June 11, 2018 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT APTINYX INC. [?] Shares of Common Stock, par value $0.01 per share [?], 2018 J.P. Morgan Securities LLC Cowen and Company, LLC Leerink Partners LLC BMO Capital Markets Corp. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington |
|
| June 11, 2018 |
Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# . COMMON STOCK PAR VALUE $0.01 COMMON STOCK Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * Certificate Number ZQ00000000 APTINYX INC. INCORPO |
|
| June 11, 2018 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APTINYX INC. Aptinyx Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Aptinyx Inc. and that this corporation was originally |
|
| June 11, 2018 |
Exhibit 10.3 APTINYX INC. 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Aptinyx Inc. 2018 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of Aptinyx Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stock?). 314,697 shares of Co |
|
| June 11, 2018 |
Exhibit 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is made by and between Aptinyx Inc. (the ?Company?) and (the ?Executive?). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements and understa |
